Since 1992, 1 there have been nearly 25 consecutive years of decline in overall incidence and mortality rates for all types of cancer. 2 In addition, the number of people living 5 years or more after a cancer diagnosis is projected to increase 31% by 2026, 3 representing an increase of more than four million survivors in less than a decade. Cancer research, including the advances in this report, will help make progress possible.
Advance of the Year: Progress in Treating Rare Cancers
This year, ASCO names Progress in Treating Rare Cancers as the Advance of the Year. In the United States, rare cancers account for approximately 20% of all cancers diagnosed each year, and incidence rates vary worldwide. 4 Progress has historically lagged behind the achievements made in more common cancers; however, five major studies this past year offer significant steps forward, making this a notable year for advances in rare cancers: 1. A new combination of targeted therapies for a rare, hard-to-treat form of thyroid cancer produced responses in more than two thirds of patients. 2. Sorafenib became the first treatment to improve progression-free survival for desmoid tumors, a rare type of sarcoma. 3. A new therapy that delivers targeted radiation to tumor cells, lutetium-177 ( 177 Lu)-Dotatate, lowered the risk of disease progression or death by 79% for patients with advanced, somatostatin receptor-positive midgut neuroendocrine tumors, compared with standard treatment. 4. Trastuzumab, a standard treatment for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, significantly slowed progression of HER2-positive uterine serous carcinoma. 5. The first promising therapy-the colony-stimulating factor-1 (CSF-1) inhibitor pexidartinib-for a rare cancer of the joints known as tenosynovial giant cell tumor showed an overall response rate of 39.3% in patients taking pexidartinib versus 0% in patients taking a placebo.
This progress in rare cancers can be attributed, in part, to ongoing efforts of several major initiatives sponsored and led by the National Institutes of Health (NIH), including The Cancer Genome Atlas (TCGA). The systematic characterization of a broad range of tumors by TCGA has led to effective targeting of activated pathways. Future funding of these and other similar efforts is vital to accelerating progress in rare cancers.
Additional Major Advances
Landmark advances in molecular diagnostics continue, with the most significant achievement made as a result of the TAILORx (ClinicalTrials.gov identifier: NCT00310180) breast cancer study. This study demonstrated that as many as 70% of women with hormone receptor-positive, nodenegative breast cancer could safely forgo adjuvant chemotherapy based on results from a 21-gene assay.
Immunotherapy advances continue to grow, expanding to cancers in which there have been few immunotherapy treatment successes to date:
• A new combination immunotherapy regimen was proven to boost overall survival in patients with renal cell cancer, gaining US Food and Drug Administration (FDA) approval and becoming the new standard of care. • An investigational programmed cell death-1 (PD- 1) inhibitor showed promise for advanced squamous cell cancer of the skin, which has few other treatment options.
New successes are being achieved with targeted therapies, including the introduction of medicines that delay the progression of breast and lung cancers.
The growing microbiome research field has identified specific bacteria possibly associated with risk for certain head and neck cancers. Other advances of note are listed in Appendix Table A1 (online only).
ASCO Research Priorities to Accelerate Progress
For the first time, ASCO is identifying areas on which future research efforts should be focused to help accelerate progress against cancer. These priority areas, listed in no particular order, address an unmet need or help fill a knowledge gap in areas critical to improving patient care and outcomes:
1. Identify strategies that better predict response to immunotherapies. 2. Better define the patient populations that benefit from postoperative (adjuvant) therapy. 3. Translate innovations in cellular therapies to solid tumors. 4. Increase precision medicine research and treatment approaches in pediatric cancers. 5. Optimize care for older adults with cancer. 6 . Increase equitable access to cancer clinical trials. 7. Reduce the long-term consequences of cancer treatment. 8. Reduce obesity and its impact on cancer incidence and outcomes. 9. Identify strategies to detect and treat premalignant lesions.
These priorities build on an understanding gleaned from years of research efforts and over time will evolve with the cancer research landscape.
Cancer Research: Why Federal Support Matters
Research funded by the NIH and National Cancer Institute (NCI) has played a pivotal role in advances in cancer prevention, diagnosis, and treatment. In fact, federal funding supported three of the five advances in rare cancers and nearly one third of the studies highlighted in this year's Clinical Cancer Advances report.
What the nation's investment in research means for people with cancer:
• A 27% decline in cancer death rates (since peak in 1991) 5 • More than 130 new cancer drugs or indications approved by the FDA since 2006 6 • Increased 5-year cancer survival (two out of three people with cancer live at least 5 years after diagnosis) 7 • 15.5 million survivors of cancer (up from 11.4 million in 2006) 5 After more than 10 years of stagnant funding, Congress has demonstrated tremendous bipartisan leadership by passing four annual consecutive NIH and NCI funding increases. Most recently, lawmakers passed a $2 billion (5.4%) NIH funding increase.
Fiscal year 2019 funding 8 :
• NIH: $39.1 billion • NCI: $6.147 billion • Beau Biden Cancer Initiative: $400 million (full funding, as authorized under 21st Century Cures Act)
But our work is far from over.
• In the United States, a one-third increase in new cancer cases is expected over next decade. 9 • We are only now nearing prerecession NCI funding levels. 8,10 • Despite increases, NCI is still only able to fund a small fraction of new research proposals (12% in 2017 v 28% in 1997). 11 • There was a 75% decrease in the number of studies presented at ASCO's Annual Meeting (from 2008 to 2017) 12 that were primarily funded by NIH.
When we invest in cancer research, everyone benefits.
• Research funded by NIH generates $69 billion in new economic activity across the country and supports 402,816 jobs nationwide (directly and indirectly). 13 • Sixty-seven percent of Americans say the US government should spend more money on finding treatments and cures for cancer, even if it means higher taxes or adding to the deficit. 14 As long as cancer continues to be the life-threatening burden it is today, our nation must continue to prioritize investment in cancer research. ASCO is hopeful that recent budget increases represent a promising future of renewed focus on federally funded cancer research.
Contact your Members of Congress to urge their continued support for NIH and NCI funding. ASCO makes it easy for you to reach them directly. Just visit ASCO's ACT Network at asco.org/actnetwork.
About Clinical Cancer Advances
ASCO's Clinical Cancer Advances report highlights current trends in the field and identifies cancer research priorities that have great potential to advance progress against cancer. The report, now in its 14th edition, is developed by a 20+ member editorial board of experts in a range of cancer types, subspecialties, and care issues. The editors reviewed scientific literature published in peer-reviewed journals or presented at major medical conferences, primarily from October 2017 to September 2018, and selected advances that improve meaningful patient outcomes and have a strong scientific impact. The editors also proposed priority areas of research that address vital unmet needs in cancer care and have the potential to improve the knowledge base for clinical decision making.
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ADVANCE OF THE YEAR: PROGRESS IN TREATING RARE CANCERS
This year, ASCO names Progress in Treating Rare Cancers as the Advance of the Year. Rare cancers have been defined as those that account for less than six of 100,000 diagnosed cancers and for 20% of all cancer cases each year in the United States, although definitions and incidence rates differ around the world. 4
There is wide variation in the availability and effectiveness of treatment options for rare cancers due to the enormous diversity in clinical presentation and underlying biology. It often takes longer to recruit significant numbers of people to participate in clinical trials that are testing new treatments for rare cancers, and there are unique hurdles to developing and designing specialized therapies.
Recently, however, the decades of research progress in understanding cancer are translating into better treatments for multiple rare cancers. In fact, clinical research this past year identified effective therapies for rare forms of uterine, neuroendocrine, joint, and thyroid cancers, as well as sarcomas, which for decades have been challenging to treat effectively. What follows are some of the more prominent achievements in rare cancers this past year.
New combination of targeted therapies for rare form of thyroid cancer. Anaplastic thyroid carcinomas (ATCs) comprise less than 2% of all thyroid cancers diagnosed in the United States and have a worse prognosis than other more common forms of thyroid cancer. 15 Not only do they tend to be aggressive, but also ATCs are usually diagnosed at an advanced stage and have low 1-year survival rates. 16 This year, the FDA approved the first treatment for ATCs in almost 50 years, 17 a targeted therapy combination of dabrafenib (Tafinlar; Novartis, East Hanover, NJ), a BRAF inhibitor, plus trametinib (Mekinist; Novartis), a MEK inhibitor, for people with BRAF-mutated ATC.
The approval was based on a 2018 finding from a singlearm phase II trial. 18 The federally funded trial assessed 100 patients for eligibility and enrolled 16 patients with BRAFmutated tumors, all of whom had received prior radiation, surgery, and/or chemotherapy. Of these patients, 69% responded to the drug combination (this study was funded, in part, by NIH). At the time the study was published, seven patients, or nearly half of those enrolled, were experiencing ongoing responses to the therapy. Although overall survival and progression-free survival could not be assessed at the time, clinicians estimated that at least 80% of the patients with tumors that responded would achieve improvements in both outcomes.
Before this study, no chemotherapy treatment for ATC prolonged survival or improved quality of life. This new combination therapy has now become the standard of care for these patients. Sorafenib becomes first treatment to improve progressionfree survival for rare sarcoma. This past year brought the first randomized, global phase III trial, Alliance A091105 (ClinicalTrials.gov identifier: NCT02066181) 19 for patients with a rare type of sarcoma called a desmoid tumor. Before this federally funded trial, patients with desmoid tumors were often treated with off-label treatments. Designing a trial for desmoid tumors has historically been challenging because there are few patients to study and the tumors are known to periodically regress without systemic treatment. Indeed, approximately 20% of the cancers regressed or did not progress in patients who received a placebo in this trial (this study was funded, in part, by NCI).
Eighty-seven patients with unresectable progressive desmoid tumors were randomly assigned to receive either the tyrosine kinase inhibitor sorafenib (Nexavar; Bayer, Whippany, NJ) or a placebo. The trial achieved its primary end point, with 87% of those taking sorafenib experiencing improved 1-year progressionfree survival compared with 43% of patients on placebo.
The study authors attribute part of the success of the trial to the relatively robust patient enrollment for a rare cancer. Enrollment was facilitated by NCI's National Clinical Trials Network, a collection of organizations, hospitals, and clinicians that coordinates and supports cancer clinical trials. New radiolabeled drug substantially lowered the risk of progression or death in patients with midgut neuroendocrine tumors. Midgut neuroendocrine tumors are rare, estimated to affect fewer than three per 100,000 people annually. 20 Patients with advanced midgut neuroendocrine tumors are usually treated with somatostatin, a growth hormone inhibitor, or octreotide, a synthetic form of somatostatin that has a long-acting release.
NETTER-1 (ClinicalTrials.gov identifier: NCT01578239), an international phase III trial, 21 was the first study to evaluate the safety and efficacy of 177 Lu-Dotatate in patients with somatostatin receptor-positive midgut neuroendocrine tumors. The medicine is composed of the radioisotope 177 Lu attached to octreotide. The radionuclide-octreotide analog binds to the neuroendocrine tumor cell, enabling radiation to be directly delivered to the cancer cell, inhibiting tumor growth.
In the trial, 229 people with this disease were randomly assigned to receive either 177 Lu-Dotatate or octreotide. The estimated progression-free survival after 20 months was 65.2% in the 177 Lu-Dotatate group and 10.8% in the octreotide group. The risk of disease progression or death was 79% lower in people who received 177 Lu-Dotatate compared with those who received octreotide. Results of an interim analysis suggest longer overall survival with the new treatment; 14 deaths occurred in the group that received 177 Lu-Dotatate compared with 26 deaths in the group that received octreotide.
The FDA approved 177 Lu-Dotatate in January 2018 for treatment of adults with this type of tumor in the midgut, foregut, or hindgut. 22 A follow-up study, 23 published in September 2018, showed that the new treatment also provided important quality-of-life benefits. Investigators found that in addition to improving survival, 177 Lu-Dotatate, compared with octreotide, provided 28.8 v 6.1 months of overall better health and 25.2 v 11.5 months of better physical functioning, respectively. Trastuzumab effective for a rare form of endometrial cancer. Uterine serous carcinoma is a rare and aggressive type of cancer that accounts for 10% of endometrial cancer cases and up to 40% of recurrences and deaths from endometrial cancer. 24 The HER2 gene is overexpressed in approximately 30% of uterine serous tumors. This year, researchers demonstrated that trastuzumab (Herceptin; Genentech, South San Francisco, CA), a HER2-targeted treatment used primarily in women with HER2-positive breast cancer, is effective in these tumors.
The phase II trial 25 compared a chemotherapy combination of a platinum-based drug, carboplatin, added to paclitaxel with and without trastuzumab among 61 women with stage III or IV HER2-positive uterine serous carcinoma. The median time before disease progression was 12.6 months for women who received trastuzumab compared with 8.0 months for those who did not. This study is one of the first to demonstrate improved progression-free survival with the addition of a targeted therapy to standard platinumbased chemotherapy in women with this form of uterine cancer.
First promising therapy identified for rare cancer of the joints that typically occurs in younger adults. With global collaboration, ENLIVEN (ClinicalTrials.gov identifier: NCT02371369) 26 , a trial studying a novel treatment for tenosynovial giant cell tumors-a rare, debilitating tumor that is generally found in younger, working-age adultswas able to enroll and treat 120 patients. The disease is associated with severe loss of function and morbidity and frequently affects physical ability and job function. There is no current standard of care; two systemic therapies that have been tested in clinical trials to treat these tumors have shown poor overall responses.
Surgery remains the standard initial treatment of tenosynovial giant cell tumors. Some patients undergo multiple synovectomies (surgery to remove the membrane, or synovium, that lines a joint, most typically the knee), and some even need full-joint replacements.
The phase III federally funded trial 26 randomly assigned patients with advanced, symptomatic disease to first receive either the CSF-1 inhibitor pexidartinib or a placebo. CSF-1 is a molecule that increases the recruitment of certain tumor-promoting immune cells to the tumor; therefore, an inhibitor of CSF-1 removes these from the milieu. The overall response rate was 39.3% for patients taking pexidartinib compared with 0% for those on placebo. All patients were able to cross over to receive open-label pexidartinib in the second part of the trial. There was a statistically significant improvement in pain scores, range of motion, and physical function in patients who received the study drug (this study was funded, in part, by NIH).
The use of CSF-1 inhibitors holds promise in this disease and continues to be investigated in new clinical trials. CSF-1 inhibitors, including pexidartinib, are not yet recommended for general use as a result of serious liver toxicities that occurred in some trial participants. The toxicity is part of the focus of an ongoing study to clarify safety concerns.
Federal Funding Is Vital to Advancing Progress in Rare Cancers
Progress in rare cancers is being advanced, in part, by ongoing efforts of several major federally funded initiatives:
• TCGA cataloged key genomic changes in 33 types of cancer, of which 10 were rare cancers.
• In the MATCH (Molecular Analysis for Therapy Choice; ClinicalTrials.gov identifier: NCT02465060) precision medicine trial, patients receive treatment based on genomic changes in the tumor. More than 60% of enrollees have cancers other than the four most common types. • The DART (Dual Anti-Cytotoxic T-Cell Lymphocyte-4 and Anti-PD-1 Blockade in Rare Tumors) immunotherapy trial is studying nivolumab (Opdivo; Bristol-Myers Squibb, New York, NY) and ipilimumab (Yervoy; Bristol-Myers Squibb) in people with rare types of cancers that are usually ineligible for current immunotherapy trials.
Future funding of these and other similar efforts is vital to accelerating progress in rare cancers.
ADVANCES IN CANCER TREATMENT
Treatment advances across the spectrum of cancers have continued at a rapid pace. Lung cancer experienced significant treatment breakthroughs this year, primarily in immunotherapy, as it has in the past several years. Other immunotherapy trials brought new treatment options to patients with a range of solid tumor and blood cancers. In addition, in 2018, a Nobel Prize was awarded to the researchers who found that the immune system could be harnessed to attack cancer, highlighting the significance of research advances seen in this area.
Progress in treatment was also seen in systemic chemotherapy, targeted chemotherapy, surgery, and radiotherapy.
Immunotherapy Advances
This year, research expanded the reach and impact of multiple forms of immunotherapy. Key studies of checkpoint inhibitors showed survival gains when the medicines were TAPUR ASCO's Targeted Agent and Profiling Utilization Registry (TAPUR; ClinicalTrials.gov identifier: NCT02693535) Study continues to enroll patients and achieve milestones as patient outcomes are reached. The TAPUR Study evaluates antitumor activity of commercially available, targeted anticancer drugs when used outside of their US Food and Drug Administrationapproved indications. It aims to identify new uses for existing, effective treatments that target tumor genomic profiles.
More than 1,600 participants have been registered and more than 1,200 patients treated with a TAPUR Study drug. On the basis of treatment responses in stage I, patient cohorts are either expanded to stage II for additional study or permanently closed. To see the full list of patient cohort updates, go to tapur.org/news. offered earlier in the course of treatment and in combination with other treatments, including other immunotherapies and chemotherapy. In adoptive cell therapy, longer term data provided deeper insight on the benefits and risks of this approach in various blood cancers. The year also brought the FDA approval of several new immunotherapies (Appendix Table A2 , online only).
Checkpoint inhibitors proven valuable as initial therapy for advanced lung cancer. In advanced non-small-cell lung cancer (NSCLC), two trials demonstrated that checkpoint inhibitor therapies have a role in first-line treatment.
The phase III IMpower150 (ClinicalTrials.gov identifier: NCT02366143) trial 27 tested combinations of carboplatin, paclitaxel, and bevacizumab (Avastin; Genentech) with or without the immunotherapy agent atezolizumab (Tecentriq; Genentech), which targets the programmed death ligand-1 (PD-L1) protein. Median progression-free survival was 8.3 months for all patients who received the standard treatment plus immunotherapy compared with 6.8 months for those who received conventional chemotherapy with bevacizumab.
In another phase III trial, KEYNOTE-189 (ClinicalTrials.gov identifier: NCT02578680), 28 researchers randomly assigned participants to receive chemotherapy drugs pemetrexed and cisplatin or carboplatin, followed by the PD-1 inhibitor pembrolizumab or a placebo. Both 1-year overall survival rate (69.2% in the pembrolizumab group v 49.4% in the chemotherapy-alone group) and median progression-free survival time (8.8 months in the pembrolizumab group v 4.9 months in the chemotherapyalone group) were greater among patients in the pembrolizumab group compared with patients who received chemotherapy alone.
Combination immunotherapy boosts renal cell cancer survival, established as new standard. The combination of two immunotherapy agents, nivolumab and ipilimumab, is used routinely in melanoma and is now being explored in other types of cancer. A phase III trial (CheckMate214; Clincial-Trials.gov identifier: NCT02231749) 29 evaluated this new combination immunotherapy regimen in patients with intermediate-or high-risk renal cell carcinoma, finding it improved the 18-month overall survival rate compared with the tyrosine kinase inhibitor sunitinib (Sutent; Pfizer, New York, NY), 75% for the combination v 60% for sunitinib. Remarkably, 9% of patients receiving nivolumab with ipilimumab had complete regression of the cancer.
Although not without the potential for serious toxicities, this combination of immunotherapies is now the standard of care for patients with higher risk metastatic disease. The combination recently received FDA approval in high-and intermediate-risk advanced renal cell cancer, 30 but it has not yet been established as an effective treatment for patients with low-risk disease.
Combination immunotherapy can reduce brain metastases in people with melanoma. Advanced melanoma is one of the few cancers that often metastasizes to the brain. These metastases can cause severe neurologic symptoms and lead to death within a year.
A phase II federally funded study, CheckMate204 (ClinicalTrials.gov identifier: NCT02320058), 31 looked at the combination of nivolumab and ipilimumab (the same combination tested for renal cell cancer) in people with melanoma who had untreated metastases in the brain. Clinicians observed 94 people for 14 months after completion of treatment and found that 26% of patients had no detectable brain metastases and 30% had some reduction in metastases. An impressive 82% of patients were alive after a year, whereas survival had previously been measured at weeks and months for patients receiving standard treatment (this study was funded, in part, by NCI).
Significant side effects were seen in 55% of people on the trial, some of which affected the CNS. However, the study authors noted that, as a result of the impressive benefits seen in this study, this checkpoint combination could be explored in other cancers that have spread to the brain.
Investigational PD-1 inhibitor shows promise for a skin cancer with few treatment options. In September 2018, 32 the FDA approved a new anti-PD-1 checkpoint inhibitor, cemiplimab (Libtayo; Regeneron, Eastview, near Tarrytown, NY), for cutaneous squamous cell carcinoma. The approval was based on a nonrandomized phase II trial 33 of 59 patients with metastatic disease in whom cemiplimab showed remarkable activity; tumors shrank in nearly half (n = 28) of the patients enrolled onto the trial.
Cutaneous squamous cell carcinoma is the second most common skin cancer, with more than one million patients diagnosed annually. Although most of these cancers can be cured with surgical excision, this newer treatment could have an important impact for the small but significant proportion of patients with cancer that persists or metastasizes. Prior research has shown this cancer to be relatively unresponsive to other forms of treatment, including chemotherapy.
Pembrolizumab provides greatest benefit in head and neck cancers with high PD-L1 expression. The KEYNOTE-040 (ClinicalTrials.gov identifier: NCT02252042) phase III trial compared pembrolizumab (Keytruda; Merck, Kenilworth, NJ) to standard chemotherapy in 495 people with recurrent or metastatic head and neck squamous cell carcinoma that was not responsive to platinum-based chemotherapy drugs. 34 This trial further evaluated whether a marker-PD-L1 protein expression in more than 50% of tumor cellsaffected outcomes.
The trial showed that pembrolizumab, compared with standard chemotherapy, modestly improved median overall survival time (8.7 v 7.1 months, respectively) if PD-L1 expression levels were greater than 1%. Median overall survival was approximately 4 months greater among people with tumors that expressed PD-L1 at a level greater than 50%. This is the first phase III trial to demonstrate the impact of PD-L1 expression on the efficacy of pembrolizumab in this form of cancer.
Chimeric antigen receptor T-cell (CAR-T) therapy trials show longer term benefits. In 2018, CAR-T therapy, also known as adoptive cell immunotherapy, was named the Advance of the Year by ASCO. Unlike checkpoint inhibitors, this form of immunotherapy boosts the ability of the body's immune system to fight cancer using a patient's own genetically reengineered T cells.
An early-phase clinical trial formed the basis of the 2017 FDA approval 35 of the anti-CD19 CAR-T therapy tisagenlecleucel (Kymriah; Novartis) for acute lymphoblastic leukemia, the most common cancer in children. CD19 is an important biomarker for this cancer because it is present on the surface of malignant B cells, thus making it an effective target for CAR-T cells.
More recently, a global phase II trial (ClinicalTrials.gov identifier: NCT03123939) 36 confirmed preliminary data and established the feasibility of delivering this treatment to children. Of the 75 children in the trial, 81% showed decreased signs and symptoms of disease 3 months after completion of treatment. Persistence of tisagenlecleucel in the blood was observed for as long as 20 months. Overall survival decreased over time but was still significant, with 90% of children living 6 months or longer and 50% of children living 12 months or longer.
Severe but transient adverse events were observed in 73% of the children treated with tisagenlecleucel. The next step will be to test this approach in larger numbers of children and in broader age ranges so that long-term persistence of the engineered cells can be studied along with long-term patient outcomes.
ZUMA-6 (ClinicalTrials.gov identifier: NCT02926833), a phase II trial of a second type of anti-CD19 CAR-T therapy, called axicabtagene ciloleucel (Yescarta; Kite Pharma, Santa Monica, CA), enrolled 111 adults with refractory large B-cell lymphoma. 37 After a median time of 15.4 months, 82% of patients had decreased signs and symptoms of disease and 54% experienced a complete regression of disease. Furthermore, 52% of patients were alive 18 months after treatment. There were some significant adverse effects, including myelosuppression, cytokine release syndrome, and neurologic events. The FDA approved the drug for use in this population in October 2017. 38 In a third anti-CD19 CAR-T therapy trial (ClinicalTrials.gov identifier: NCT03483688), this time with a newer investigational approach, researchers isolated specific T cells that express a CD19-directed chimeric antigen receptor, called CTL019, from patients and re-engineered them in the laboratory. They reinfused the new cells into the patients as part of a phase II federally funded study. 39 Clinicians tested the CTL019 therapy in 14 adults with relapsed or refractory diffuse large B-cell lymphoma and 14 adults with follicular lymphoma. Results showed that the re-engineered CTL019 cells rapidly induced complete remission in six patients (43%) with B-cell lymphoma and 10 patients (71%) with follicular lymphoma (this study was funded, in part, by NIH). These results suggest that anti-CD19 CAR-T therapy is a promising option for people with multiple, relapsed, and refractory diffuse large B-cell lymphomas whose survival expectancies have previously been limited.
Targeted Therapy Advances
Targeting medicines to specific gene mutations in a cancer cell, as opposed to administering systemic chemotherapy that can affect every cell in the body, is still an exciting and productive frontier in oncology. With more than a decade of trials and evidence at hand, targeted therapies are expanding to new types of cancer that have been resistant to more conventional approaches.
New EGFR inhibitor delays lung cancer progression. One of the more frequently mutated genes in lung cancer is EGFR, and it can mutate in different ways and at different locations along its stretch of DNA. Some of the mutations that occur are responsive to first-generation targeted therapies, such as gefitinib (Iressa; AstraZeneca, Wilmington, DE) and erlotinib (Tarceva; Genentech). However, resistance mutations commonly emerge during treatment with these agents.
Two recent trials tested a new, second-generation drug, osimertinib (Tagrisso; AstraZeneca), that was developed to treat NSCLC with resistant or less common EGFR mutations. The oral medicine was approved by the FDA in 2018 based on a phase III international trial, FLAURA (ClinicalTrials.gov identifier: NCT02296125), 40 in which 556 patients with EGFR-positive, unresectable or metastatic NSCLC were randomly assigned to initial treatment with osimertinib or the standard EGFR-targeted treatments gefitinib or erlotinib. Progression-free survival in patients who received osimertinib was 18.9 months compared with 10.2 months in patients who received a first-generation EGFR inhibitor. A second trial of osimertinib, AURA (ClinicalTrials.gov identifier: NCT01802632), 41 primarily explored safety and effectiveness (phase I/II) with two different dosages of the medicine (80 and 160 mg) and reported that patients who received the medicine did not experience disease progression for between 16 and 19 months, regardless of the dosage.
Together, the trials showed that osimertinib almost doubled the time to disease progression achieved with older medicines. On the basis of these data, osimertinib has become the new initial treatment of choice in patients with NSCLC with certain EGFR mutations, including those not responsive to older EGFR-directed therapies.
New protein-targeted therapy delays cancer progression and gains approval for certain advanced breast cancers. HER2/neu was the first gene mutation in breast cancer for which a targeted therapy, trastuzumab, was developed.
Since trastuzumab's approval by the FDA in 1998, 42 a handful of other targeted drugs for breast cancer have been developed. Abemaciclib (Verzenio; Eli Lilly, Indianapolis, IN), a newer drug, inhibits activity of the CDK4/6 proteins that regulate the rate of cell division as opposed to targeting a specific gene mutation.
In two phase III trials, abemaciclib showed activity against previously treated metastatic hormone receptor-positive, HER2-negative breast cancer. The MONARCH 2 (ClinicalTrials.gov identifier: NCT02107703) clinical trial 43 randomly assigned 669 women with breast cancer who had disease progression, despite prior endocrine therapy, to fulvestrant (Faslodex; AstraZeneca) plus abemaciclib or fulvestrant plus a placebo. Fulvestrant is a medicine that degrades the estrogen receptor. Women taking abemaciclib plus fulvestrant had a median progression-free survival time of 16.4 months compared with 9.3 months for women who received fulvestrant plus a placebo.
The MONARCH 3 (ClinicalTrials.gov identifier: NCT02246621) trial 44 tested nonsteroidal aromatase inhibitors-either anastrozole or letrozole-plus either abemaciclib or a placebo in 493 women. In both trials, treatment with an aromatase inhibitor plus abemaciclib resulted in longer life without disease progression. The findings of these trials (and the previously conducted MONARCH 1 [ClinicalTrials. gov identifier: NCT02102490] trial) led to FDA approval in February 2018 of abemaciclib in combination with an aromatase inhibitor. 45 Novel combination treatment shows promise for elderly patients with acute myeloid leukemia (AML). Combining medicines with innovative mechanisms of action can lead to effective therapies in certain unique or hard-to-treat groups of patients. In AML, this approach is being pursued to improve care for older patients who are generally not healthy enough to tolerate conventional therapies.
Medicines such as azacytidine (Vidaza; Celgene, Summit, NJ) and decitabine (Dacogen; Otsuka Pharmaceutical America, Rockville, MD), which affect the DNA methylation process, have shown some short-lived benefit in these patients. To further boost their therapeutic impact, researchers turned to an oral medicine called venetoclax (Venclexta; Genentech), which provokes cancer cell death by targeting the BCL2 protein.
A phase I trial (ClinicalTrials.gov identifier: NCT02203773) 46 combining azacytidine and venetoclax was designed to see whether this combination could boost remission of AML in older people. Of the 57 patients initially enrolled, 35 patients achieved either complete remission or complete remission with incomplete restoration of bone marrow function. These results were promising enough to convince the investigators to continue studying this combination in larger groups of people.
Other Therapeutic Approaches
Beyond immunotherapy and targeted treatments, clinical trials brought new advances in several hard-to-treat cancers using a broader range of treatment strategies.
New modified chemotherapy regimen proves more potent in pancreatic cancer. For patients with pancreatic cancer who have had surgery, the standard postsurgery treatment until now has been gemcitabine, a chemotherapy drug that blocks tumor cells from multiplying. Despite this treatment, more than 70% of patients typically experience cancer recurrence within 2 years of surgery. This year, a trial identified a new, more effective approach using a combination of chemotherapy drugs.
In a phase III clinical trial (ClinicalTrials.gov identifier: NCT01526135) 47 Although Medicare and private and commercial payers already guarantee this coverage, Medicaid is the only major payer that is not required by federal law to do so. With Medicaid insuring nearly one fifth of the US population, it is critical to close this gap and ensure that Medicaid beneficiaries have access to trials that may be the best clinical option for many patients.
higher toxicities. On the basis of this trial, modified FOL-FIRINOX is now considered the standard of care after pancreatic cancer resection.
Less is more for certain ovarian cancers. In ovarian cancer, a recent trial (ClinicalTrials.gov identifier: NCT 00565851) 48 helped resolve an ongoing debate about whether aggressive surgery is beneficial. This phase III clinical trial evaluated the benefit of secondary surgery for women with ovarian cancer that was successfully treated with platinumbased chemotherapy, with or without bevacizumab, in patients who were physically able to undergo additional surgical resection.
Researchers randomly assigned 485 women to secondary surgery followed by paclitaxel and carboplatin chemotherapy or chemotherapy with no additional surgery.
There was no increase in survival with additional surgery; the median overall survival time was 53.6 months for patients who received the secondary surgery compared with 65.7 months for patients who only received chemotherapy.
These findings may be practice changing, as earlier studies and conventional wisdom previously supported secondary cytoreductive surgery. Although survival was over a year longer with just chemotherapy, the results need to be confirmed by studies that are now ongoing.
Two drugs show promise in men with prostate cancer resistant to hormone therapy. For men with early-stage prostate cancer, there is evidence demonstrating the benefits and risks of watching and waiting before commencing treatment. If prostate-specific antigen (PSA) levels rise, indicating that the cancer has progressed, the disease is typically treated with radiation, surgery, or drugs that block the androgen hormones fueling the cancer's growth. In patients who have received hormone therapy, however, if such cancers do not respond, researchers have determined that approximately 40%, or more than 250,000 men in the United States, will develop metastases and potentially die within a 16-month time interval.
Two phase III trials (ClinicalTrials.gov identifier: NCT01946204 and NCT02003924, respectively) evaluated apalutamide (Erleada; Janssen Biotech, Horsham, PA) 49 and enzalutamide (Xtandi; Astellas Pharma, Tokyo, Japan) 50 versus placebo in men with nonmetastatic prostate cancer who have increasing PSA levels and in whom the cancer is resistant to hormone therapy. These medicines work by blocking a key driver of prostate cancer, the androgen receptor, in a much more potent fashion than previous drugs.
Each study found a significant improvement in metastasisfree survival. Median metastasis-free survival was 40.5 months in the apalutamide group compared with 16.2 months in the placebo group in one study. In the other study, median metastasis-free survival was 36.6 months in the enzalutamide group compared with 14.7 months in the placebo group.
These results led to the FDA approval of apalutamide in February 2018, 51 as well as a broadening of the FDA label for enzalutamide in July 2018, 52 meaning that it could be used for indications beyond the initial approval for latestage castration-resistant prostate cancers. The researchers' next aim is to analyze molecular and circulating markers from blood samples to identify patients who benefited the most from the therapies.
FDA Approvals
The number of new FDA approvals in oncology continues at a rapid pace. From November 2017 through October 2018, the FDA approved 11 new cancer therapies and 39 new uses of cancer therapies (Appendix Table A2 ). In the same time frame in the previous year, there were 18 new cancer therapies and 13 new uses approved.
Our nation must continue to invest in research so that we can make certain that cutting-edge cancer treatments are available to all patients. Federal research is the roadmap to renewed hope that you can bring to people's bedsides each and every day.
-Representative Paul Tonko (D-NY)
ADVANCES IN DIAGNOSTICS
This year marked a major advance with a molecular test that can help many women with early-stage breast cancer safely forgo chemotherapy. There were also advances in the use of liquid biopsies for refining treatment in several major cancers.
Investigational blood test detects common cancers. Early detection of cancers by a simple blood test, often called a liquid biopsy, is another facet of diagnostics that has been gaining traction. Some recent studies have shown that a blood test that assesses multiple potential markers, including both genes and proteins, may be sensitive enough to potentially diagnose cancer. One such test, CancerSEEK, was able to detect eight common types of cancer by assessing eight protein biomarkers and tumor-specific mutations in circulating DNA found in blood samples.
The federally funded study 53 analyzed the blood of approximately 1,000 patients previously diagnosed with cancers of the ovary, liver, stomach, pancreas, esophagus, colorectum, lung, or breast and compared those results to blood sample analyses from 850 healthy people. Cancer-SEEK was able to detect evidence of cancer with a sensitivity (the positive results were accurate) of 69% to 98% and a specificity (the negative results were accurate) of greater than 99% (this study was funded, in part, by NCI and the National Institute of General Medical Sciences). The authors suggest that CancerSEEK may be able to be developed as a universal blood test for the early diagnosis of cancer.
Major trial identifies women who can safely skip adjuvant chemotherapy for breast cancer. An international, federally funded clinical trial 54 of more than 10,000 women with hormone receptor-positive, HER2-negative, lymph nodenegative breast cancer delivered practice-changing findings. The results of the trial showed that women older than age 50 years with low and intermediate recurrence risk scores (0 to 10 and 11 to 25, respectively), as determined by a 21-gene expression assay, did not benefit from adding adjuvant chemotherapy to standard adjuvant endocrine therapy (this study was funded, in part, by NCI).
The results from TAILORx also showed that women age 50 years and younger, especially those with recurrence scores of 21 to 25, could accrue some benefit from adjuvant chemotherapy.
This clinical trial is a significant advance in precision medicine. Up until now, women older than age 50 years with scores between 11 and 25 on the Oncotype DX (Genomic Health, Redwood City, CA) gene expression assay were usually recommended to receive adjuvant chemotherapy. These women can now safely receive just endocrine therapy, which both reduces the cost of care and spares them the short-and long-term adverse effects of chemotherapy.
ADVANCES IN PATIENT CARE
Recent findings point to new approaches that improve patient outcomes and quality of life during and after treatment. These include ways to ease treatment for people with blood cancers, to mitigate hearing loss in children undergoing intensive chemotherapy, to lessen repeated testing of people who have had surgery for colorectal cancer, and to better inform people about the risks of alternative medicine.
Palliative interventions beneficial among patients undergoing potentially curative treatment of blood cancer.
Building on prior research showing the benefits of early initiation of supportive care, including palliative care, in patients with advanced cancer, a new study, SHEILD (ClinicalTrials.gov identifier: NCT02207322), 55 looked at the approach in 160 people with hematologic malignancies undergoing potentially curative hematopoietic stem-cell transplantation.
The study randomly assigned people to routine transplantation care or transplantation care with integrative supportive and palliative care. At the start of the study and at 6 months after transplantation, the investigators assessed quality of life, anxiety, and symptom burden, among other factors. The researchers found that patients in the intervention arm (integrated palliative care) had lower depression symptoms and lower post-traumatic stress disorder symptoms, but there was no benefit for quality of life or anxiety. On the basis of this study, incorporating inpatient palliative care into routine transplantation could lead to decreased psychological distress that typically persists 6 months after the transplantation.
Alternative medicine is not a substitute for conventional therapy. Studies quantifying benefits and risks of alternative and unproven therapies in many cancers have not been extensive. An observational study 56 of data from the National Cancer Database confirmed that there is a much higher likelihood of death among patients diagnosed with early-stage or curable breast, lung, or colon cancers who only received alternative medicine, compared with those treated with standard therapy. In this study, which included data from 840 patients treated between 2004 and 2013, authors defined alternative therapies as unproven cancer treatments given by nonmedical personnel.
The 5-year survival rate for patients treated with alternative medicine was 54.7% compared with 78.3% for those who received standard therapy. Cancer-specific 5-year survival rates were also higher for patients with breast, lung, and colorectal cancer who were treated with conventional therapy. The rates were lower, however, for patients treated with conventional therapy for prostate cancer. Researchers suspect this can be attributed to the typically slower progression of prostate cancer.
According to the National Cancer Opinion Survey conducted by ASCO in 2018, nearly four in 10 Americans, or 39%, believe cancer can be cured solely through alternative therapies, such as enzyme and oxygen therapy, diet, vitamins, and minerals. The survey also found that younger people (47% of survey respondents age 18 to 37 years and 44% of participants age 38 to 53 years) are the most likely to hold these views. 14 The National Cancer Database study provides important information to help guide patient decisions about care and might help mitigate concerns about the use of conventional therapies compared with alternative approaches. The researchers also emphasized that alternative medicine should not be confused with integrative or complementary medicine.
New combination treatment halves hearing loss risk in children with hepatoblastoma. Hepatoblastoma, a form of liver cancer that develops in infants and children, can often be treated effectively with a combination of cisplatin chemotherapy and surgery. Cure rates for standard-risk hepatoblastoma are now consistently greater than 80%, and close to 50% of children with high-risk disease can also be cured. The intensive use of cisplatin in young children, however, is associated with irreversible hearing loss.
cisplatin or cisplatin plus sodium thiosulfate treatment (this study was funded, in part, by NIH and the US Department of Veterans Affairs). Sodium thiosulfate is a basic chemical compound that is on the WHO list of essential, safe medicines. 58
In the study, the two medicines were given over four courses before surgery and two courses after surgery. Hearing loss of any grade was nearly halved with the combination treatment. Grade 1 or greater hearing loss (on a scale with grade 1 being the least loss of hearing and grade 4 the most) occurred in 33% of children in the cisplatin plus sodium thiosulfate group compared with 63% of children in the cisplatin-alone group. Survival was not affected by adding sodium thiosulfate to cisplatin, suggesting that the addition did not have a tumor-protective effect.
Surveillance of postsurgical patients with colorectal cancer could effectively be lessened. The optimal frequency of follow-up testing for people who have been treated for colorectal cancer has not been quantified. In an unblinded trial, COLOFOL (ClinicalTrials.gov identifier: NCT00225641), 59 conducted in Sweden, Denmark, and Uruguay, more than 2,500 people with stage II or III colorectal cancer were randomly assigned to either lowfrequency follow-up (computed tomography of the chest, abdomen, and pelvis and measurement of carcinoembryonic antigen, a blood antigen, at 12 and 36 months after surgery) or high-frequency follow-up (the same tests at 6, 12, 28, 24, and 36 months after surgery).
Primary outcomes showed no difference in the number of deaths overall after 5 years as a result of colorectal cancer or any other cause.
This finding-that less frequent surveillance does not result in worse survival outcomes-indicates that it is safe for patients to have less testing over time, a finding that should reduce health care costs as well as reduce patients' exposure to unnecessary radiation from computed tomography scans.
I am proud that the 21st Century Cures Act included funding increases for NIH signed into law on a bipartisan basis. Oncologists and lawmakers both care about people with cancer, and, together, we can work toward even greater increases for NIH to find answers that will improve treatments patients receive.
-Representative Fred Upton (R-MI)
THE MICROBIOME AND CANCER
The human body's microbial community is thought to have such intricate and profound effects on human health that it is often referred to as the hidden organ. By evolving together over thousands of years, indwelling microbes and their human hosts have developed a mutually beneficial relationship. The relationship is so intertwined that one can think of the human body as one superorganism made of both human and microbial cells. 60 From birth through the early years of life, countless different bacteria colonize the body. These trillions of microbes form the human microbiome, which is influenced by genetic, environmental, and lifestyle factors (such as diet, medication use, and physical activity). Because of this, the composition of the microbiome varies from one person to the next. 60 Recent research has shown that the microbiome plays an important role in maintaining and influencing key physiologic activities, including normal metabolism and immune function. Laboratory and clinical evidence suggest that changes in specific organisms in the microbiome may lead to the development of disease, including cancer.
When it comes to cancer, the body's microbes can be both harmful and beneficial. Although certain microbes may promote cancer growth, others seem to bolster the body's immune defenses against cancer or help cancer treatments work better. 60 Microbiome research is a young and fast-growing field; however, it is not yet clear that specific microbes have beneficial or detrimental roles in cancer development. As such, research efforts are expanding.
The microbiome shapes cancer risk. While much work has focused on the gut microbiome, researchers have found that changes in oral and vaginal microbiomes could be associated with modified disease risk as well. Many investigations have found links between the abundance of specific organisms that comprise the microbiome and the risk of colon, squamous cell, and esophageal cancers. These observations suggest that modulating the microbiome in individuals at high risk of developing certain malignancies may be a cancer prevention strategy worth exploring.
Over the past several years, two federally funded studies looked at oral mouthwash samples from people to determine the presence of specific bacterial microbes. One study enrolled 383 patients and controls to examine how the microbiome might influence head and neck squamous cell cancer. 61 Researchers noted that people who developed this disease were more often current tobacco smokers, consumed moderate to high levels of alcohol, and were human papillomavirus type 16 positive (this study was funded, in part, by NCI).
For patients with head and neck squamous cell cancer, researchers found that while the overall composition of the microbiome was not associated with increased cancer risk, an abundant amount of Corynebacterium and Kingella bacteria was associated with a decreased risk.
Another study looked at the prevalence of oral bacteria in 106 patients with esophageal adenocarcinoma (EAC) or esophageal squamous cell carcinoma (ESCC) 62 (this study was funded, in part, by NCI). The periodontal pathogen Tannerella forsythia was associated with higher risk of EAC, whereas depletion of Neisseria and Streptococcus pneumoniae bacteria was associated with lower EAC risk. For ESCC the abundance of the periodontal bacterium Porphyromonas gingivalis conveyed higher risk of the cancer.
It is too soon to offer a strategy for using the microbiome to modify cancer risk or progression; however, the findings of these two studies could inform the basis for future research on effective approaches for prevention or treatment of some head and neck cancers.
Though there are still many questions to answer about the microbiome, it is known that a lifestyle involving a well-balanced diet and exercise can promote a diverse microbiome associated with good health. In the future, cancer care may even include an analysis of the patient's microbiome at diagnosis to inform personalized treatment planning. ASCO will continue to monitor progress in this complex but fascinating field of research and will report on progress in understanding the microbiome and cancer in future editions of Clinical Cancer Advances.
NINE RESEARCH PRIORITIES TO ACCELERATE PROGRESS AGAINST CANCER
As the organization that represents and connects the global community of clinicians who discover new treatments for cancer and deliver the latest advances to patients, ASCO has developed, for the first time, a set of Research Priorities to Accelerate Progress Against Cancer. These priorities represent promising areas of research that urgently need greater attention and have the potential to significantly improve the knowledge base for clinical decision-making and address vital unmet needs in cancer care.
The current list reflects ASCO's mission-conquering cancer through research, education, and promotion of the highest quality patient care-as well as the diversity of needs and opportunities in oncology. It focuses on cancer prevention strategies, increasing equity in access to and participation in research, optimizing treatment, and improving long-term health for the growing number of cancer survivors around the world.
Over time, ASCO's Research Priorities will evolve with the cancer research landscape and will be periodically updated to reflect advancing science and unmet clinical needs. Current priorities are listed in no particular order.
Identify Strategies That Better Predict Response to Immunotherapies
Cancer immunotherapy encompasses a broad range of medicines and treatment approaches, including vaccines, immune checkpoint inhibitors, and most recently, cellular therapies. These interventions have improved the outlook for multiple cancers, producing long-lasting remissions that can last for years in some patients. At present, however, long-term disease control occurs in just a minority of patients. In addition, immunotherapies can cause substantial adverse effects that can be life-threatening and, in some cases, permanent. Methods to identify patients most likely to benefit from immunotherapy and those at high risk for severe adverse events are urgently needed. The ability to adequately assess benefits and risks of immunotherapy for each individual will lead to better outcomes for patients.
Priority focus areas:
• Identify factors that predict response, long-term disease control, prolonged survival, treatment resistance, and adverse events for all types of immunotherapies • Develop blood-and tissue-based biomarkers and novel immune-response signatures that predict treatment benefit • Develop predictive models and algorithms that assign risk of severe immune-related toxicities based on readily available patient data
Better Define the Patient Populations That Benefit From Postoperative (Adjuvant) Therapy
A wide range of therapies are recommended to patients after surgery. These therapies, referred to as adjuvant treatments, aim to reduce the risk of recurrence and cancer-related death. Although such therapy has been associated with dramatic improvements in survival for some patients, studies have shown that the risks can outweigh the benefits for others. It is important to ensure that patients who receive adjuvant therapy are the ones most likely to benefit. Eliminating its use in those who do not benefit will be an important step in optimizing care and eliminating unnecessary adverse effects and costs for patients in whom the benefits are unlikely to outweigh the risks.
Priority focus areas:
• Determine factors that identify patients most likely to benefit, or those unlikely to benefit, from adjuvant therapy, including, but not limited to, clinical, pathologic, genomic, biochemical, immunologic, and environmental or social factors • Develop analytically and clinically valid biomarker tests with proven clinical utility to identify recurrence risk after treatment of the primary tumor and determine the best options for patients with different degrees of risk
Translate Innovations in Cellular Therapies to Solid Tumors
limited data to show whether this strategy can be expanded to patients with solid tumors.
Priority focus areas:
• Identify and validate novel antigenic targets uniquely present in solid tumors • Explore the safety and activity of promising cellular therapies in solid tumors • Develop strategies that mitigate current challenges in delivering cellular therapies to patients, including exploring the use of cellular products that do not have to be individually manufactured for each patient • Examine and optimize the cancer care delivery systems needed to safely administer cellular therapies to all who might benefit
Increase Precision Medicine Research and Treatment Approaches in Pediatric Cancers
Genomic tools have been widely deployed for adult patients to characterize common mutations across different types of cancer. In certain cancers, the use of these tools has accelerated development of new targeted therapies that have improved and extended patients' lives. Despite this success in adult patients, precision medicine treatment approaches have yet to be widely integrated into the treatment of pediatric cancers.
Priority focus areas:
• Identify genomic or other molecular alterations in pediatric cancers that can serve as potentially actionable treatment targets • Develop effective therapeutic agents that can target genomic or other molecular alterations in childhood cancers • Explore the efficacy of existing targeted therapies in pediatric patients with tumors that have mutations shown to be responsive to medicines that work in adult populations
Optimize Care for Older Adults With Cancer
Although adults age 65 years and older represent the majority of people with cancer, few cancer clinical trials focus specifically on this population. Older patients who do participate in clinical trials are generally not representative of the older patients who oncologists typically see in daily practice. As a result, clinicians face challenges applying clinical trial data to older patients who may have additional health conditions, varying levels of functional ability, and different goals from clinical trial participants. The lack of evidence in this area combined with the inherent diversity of aging populations impedes the delivery of high-quality care for the largest and most rapidly growing segment of patients with cancer.
Priority focus areas:
• Develop standardized methods to characterize physiologic aging, such as geriatric assessment and biomarkers of aging, to more reliably predict risk of treatment-related adverse effects in older patients with cancer
• Investigate the impact of cancer treatment on physical function, cognition, and quality-of-life to inform tolerability of cancer therapies in older people • Investigate the efficacy and toxicity of therapies among older adults most under-represented in clinical trials, such as those with impaired functional status, comorbidities, or frailty • Conduct clinical trials testing the role of geriatric assessment-guided management to improve outcomes using personalized care; important focus areas include strategies that minimize undertreatment of fit patients and overtreatment of vulnerable or frail patients, supportive care interventions, and care delivery interventions
Increase Equitable Access to Cancer Clinical Trials
Certain patient populations are consistently under-represented in cancer clinical trials. These include patients from racial and ethnic minorities, rural areas, and lower socioeconomic groups and patients older than age 65 years as well as adolescents and young adults age 15 to 39 years. Decreased representation among these groups can limit access to the promising treatments offered through these trials and means that research findings may not fully account for the diversity of biologic, social, and cultural factors that influence outcomes. Additional research is needed to ensure that every patient with cancer, regardless of race, ethnicity, age, geographic location, or socioeconomic status, benefits from research advances.
Priority focus areas:
• Advances in cancer treatment have resulted in a record number of cancer survivors-more than 15.5 million. 63 Although this is a tremendous accomplishment, survivors still face long-term consequences of cancer, including adverse effects of cancer therapies that affect quality of life. These adverse effects, which commonly include peripheral neuropathy, cognitive impairment, and cardiotoxicity, pose a substantial burden not only to patients but also to the health care system.
• Identify genetic variants associated with increased risk of treatment-related toxicities • Deepen understanding of the underlying mechanisms of toxicities from targeted treatments, determine their contribution to long-term effects, and develop novel strategies to mitigate or eliminate such toxicities • Develop new tools to facilitate long-term tracking of patient outcomes that include patient-reported outcome measures
Reduce Obesity's Impact on Cancer Incidence and Outcomes
The incidence of obesity has dramatically increased over the past several decades. 64 Despite being the second leading preventable cause of cancer, a recent ASCO survey 14 found that only 35% of Americans recognize excess body weight as a cancer risk factor. Obesity is associated with poorer cancer survival and can contribute to increased risk of treatment-related adverse effects. If current trends continue over the next 20 years, it is estimated that obesity will lead to more than 500,000 additional cases of cancer each year in the United States 65 and will surpass smoking as the leading preventable cause of cancer.
Priority focus areas:
• Improve the understanding of the mechanisms through which weight and energy balance, including physical activity and dietary factors, contribute to cancer development and progression • Investigate how obesity affects response to therapy, risk of cancer recurrence, and long-term cancer outcomes • Assess the impact of energy balance interventions, such as weight loss, increased physical activity, and improved dietary quality, on cancer risk, recurrence, and mortality • Identify effective interventions that optimize energy balance in people at risk and who are living with cancer
Identify Strategies to Detect and Treat Premalignant Lesions
Many cancers begin as high-risk lesions that invariably progress to invasive cancer. Currently, little is known about the genetic makeup, heterogeneity, microenvironment, and what causes some of these lesions to progress to invasive cancer. Increased knowledge will help guide new approaches to intercept and eradicate high-risk lesions before their transformation to malignancy.
Priority focus areas:
• Identify specific molecular pathways that drive progression of preinvasive lesions to invasive cancer and develop interventions that can delay or prevent progression to malignancy • Identify features of the microenvironment of premalignant lesions that are associated with progression to invasive disease • Investigate novel methods for evaluation of premalignant lesions to better inform the risk or likelihood of progression to invasive disease
AFFILIATIONS A PATH FORWARD TO INCREASE ACCESS TO CLINICAL TRIALS
ASCO is working with key stakeholders to address under-representation of certain populations in clinical trials. Recently, the society issued a policy statement on the financial barriers that prevent patients from participating in clinical trials. ASCO's recommendations include the following: improve insurance coverage of routine care costs for clinical trial participants, increase transparency about out-ofpocket costs, remove impediments to ethically appropriate direct payments to patients, and incentivize research on the financial costs of trial participation.
This statement builds on ASCO's work with Friends of Cancer Research to address under-representation in cancer clinical trials through more inclusive eligibility criteria. The two organizations developed comprehensive recommendations to address eligibility criteria in the following five areas: minimum age requirements for trial enrollment, HIV/AIDS status, brain metastases, organ dysfunction, and prior and concurrent malignancies. Meta-analysis of 88 trials involving more than 60,000 women with estrogen receptor-positive breast cancer who were disease free after 5 years of endocrine therapy showed that recurrences continued to occur at a relatively steady rate 5 to 20 years after completion of therapy. Abbreviations: CPS, combined positive score; EGFR, epidermal growth factor receptor; FDA, US Food and Drug Administration; HER2, human epidermal growth factor receptor 2; PD-L1, programmed death ligand-1.
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